Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

Biden proposes Medicare and Medicaid cover weight loss drugs
Axios
Tue, 11/26/24 - 09:51 am
Tags:
Joe Biden, Medicare, Medicaid, obesity, Novo Nordisk, Eli Lilly, Zepbound, Wegovy, Ozempic
Pfizer led industrywide sales surge in Q3 after several quarters of dominance by Eli Lilly, Novo Nordisk
Fierce Pharma
Mon, 11/25/24 - 11:43 am
Tags:
Pfizer, earnings, Eli Lilly, Novo Nordisk
Drugmakers and pharmacists battle over who gets to make obesity drugs
NPR
Wed, 11/20/24 - 11:21 am
Tags:
Novo Nordisk, Eli Lilly, obesity, weight loss, GLP-1 agonists, compounded drugs
Lilly's lipoprotein-blocking heart med posts midstage win, turning up heat on potential AZ showdown
Fierce Biotech
Tue, 11/19/24 - 11:16 am
Tags:
Eli Lilly, lipoproteins, clinical trials, cholesterol, muvalaplin
New Alzheimer's prevention trial receives $74.5 million NIH grant
Drugs.com
Sun, 11/17/24 - 09:22 pm
Tags:
Eli Lilly, Alzheimer's disease, NIH, clinical trials
Survey Finds Most GLP-1 Users Discontinue Drug Before Reaching Goal Weight
Xtalks
Fri, 11/15/24 - 11:27 am
Tags:
Omada Health, GLP-1 agonists, obesity, weight loss, Novo Nordisk, Eli Lilly, Ozempic, Zepbound, Mounjaro, Wegovy
Lilly sues US agency over blocking of drug-rebate program
MSN/Reuters
Fri, 11/15/24 - 11:08 am
Tags:
Eli Lilly, 340B, HRSA, drug rebates, legal
Eli Lilly’s weight-loss drug helps nearly 99% of patients remain diabetes-free
Pharma Live
Thu, 11/14/24 - 11:21 am
Tags:
Eli Lilly, weight loss, tirzepatide, Mounjaro, Zepbound, diabetes
Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’
Pharma Voice
Tue, 11/12/24 - 09:49 am
Tags:
Pfizer, Eli Lilly, telehealth, DTC
Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
Pharma Voice
Thu, 11/7/24 - 11:12 am
Tags:
M&A, Vertex Pharmacuticals, Alpine Immune Sciences, Eli Lilly, Morphic, Novartis, MorphoSys, Mariana Oncology, AstraZeneca, Fusion Pharmaceuticals, Lundbeck, Longboard Pharmaceuticals, AbbVie, Aliada Therapeutics
FDA adds aspiration warning to Ozempic, Mounjaro and other GLP-1 labels
Beckers Hospital Review
Wed, 11/6/24 - 08:01 pm
Tags:
FDA, warnings, aspiration, Ozempic, Wegovy, Saxenda, Mounjaro, Novo Nordisk, Eli Lilly
States slow to cover GLP-1s for weight loss
Axios
Wed, 11/6/24 - 11:37 am
Tags:
Medicaid, GLP-1 agonists, Novo Nordisk, Eli Lilly, Wegovy, Zepbound
Lilly shares fall as obesity drug sales miss forecasts
BioPharma Dive
Wed, 10/30/24 - 11:52 am
Tags:
Eli Lilly, earnings, obesity, Zepbound, Mounjaro
Dueling IL-23 data drop as Lilly, J&J await FDA decisions in Crohn's
First Word Pharma
Mon, 10/28/24 - 06:24 pm
Tags:
Eli Lilly, JNJ, Crohn's Disease, FDA, clinical trials, Tremfya, Omvoh
J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups
Fierce Pharma
Fri, 10/25/24 - 11:43 am
Tags:
JNJ, Eli Lilly, Tremfya, immunology, plaque psoriasis, Ebglyss, atopic dermatits
How Lilly is building a brand people trust
Medical Marketing and Media
Thu, 10/24/24 - 08:20 pm
Tags:
Eli Lilly, branding, reputation, public trust
Weight-loss drugs didn't curb health costs within two years
Reuters
Thu, 10/24/24 - 11:11 am
Tags:
Novo Nordisk, Eli Lilly, Wegovy, Zepbound, obesity
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
Reuters
Thu, 10/24/24 - 09:53 am
Tags:
Eli Lilly, Mounjaro, Novo Nordisk, Denmark, obesity
Lilly's Alzheimer's drug gets UK nod, but no NHS funding
Pharmaphorum
Wed, 10/23/24 - 11:26 am
Tags:
Eli Lilly, Alzheimer's disease, Kisunla, UK, NHS, NICE
Senators probe whether Pfizer, Lilly DTC platforms create 'potential for inappropriate prescribing'
Fierce Pharma
Tue, 10/22/24 - 11:32 pm
Tags:
Senate, Pfizer, Eli Lilly, telehealth, DTC

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.